Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

CLS001 Topical Gel

DRUG

CLS001 Topical Gel Vehicle

Trial Locations (20)

10017

Manhattan Dermatology & Cosmetic Center, New York

11790

Derm Research Center of New York, Inc., Stony Brook

27262

Dermatology Consulting Services, High Point

27612

Wake Research Associates, Raleigh

30263

MedaPhase, Inc., Newnan

33401

Kenneth R. Beer, MD, PA, West Palm Beach

33486

Skin Care Research, Inc., Boca Raton

33609

Moore Clinical Research, Inc., Tampa

33781

Belleair Research Center, Pinellas Park

37215

Tennessee Clinical Research Center, Nashville

48059

Hamzavi Dermatology, Fort Gratiot

55432

Minnesota Clinical Study Center, Fridley

77845

J & S Studies, Inc., College Station

78229

Progressive Clinical Research, PA, San Antonio

78705

Premier Research, Austin

87106

Academic Dermatology Associates, Albuquerque

90404

Clinical Science Institute, Santa Monica

91436

Encino Research Center, Encino

92117

Skin Surgery Medical Group, Inc., San Diego

99204

Premier Clinical Research, Spokane

All Listed Sponsors
lead

Maruho Co., Ltd.

INDUSTRY

NCT02066545 - Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris | Biotech Hunter | Biotech Hunter